Pharmaceutical

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Alvotech and Bioventure received the Egyptian Drug Authority's approval to produce and supply AVT02 (adalimumab), a biosimilar for Humira.

Aug 30, 2023 - 20:00
Alvotech and Bioventure gain approval for Humira biosimilar in Egypt
Alvotech and Bioventure received the Egyptian Drug Authority's approval to produce and supply AVT02 (adalimumab), a biosimilar for Humira.
Read the original article

Tags:

Previous Article

EC grants approval to Merck’s Keytruda for gastric cancer

Next Article

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Trac...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

Mar 7, 2024

Pharmaceutical drug delivery market and systems

Pharmaceutical drug delivery market and systems

Mar 24, 2024

STAT+: British Columbia to bar Americans from buying Ozempic over supply concerns

STAT+: British Columbia to bar Americans from buying Oz...

Mar 30, 2023